Volpara signs five-year SaaS contract with BreastScreen Queensland
- VolparaEnterprise contracted to BreastScreen Queensland for an initial period of five years
- Potential contracts to follow for VolparaDensity and VolparaLive
- BreastScreen Queensland is the third largest public breast screening programme in Australia
Wellington, NZ, 22nd December 2020: Volpara Health Technologies (“Volpara,” “the Group,” or “the Company”; ASX: VHT), a health technology software company whose integrated breast care platform assists in the delivery of personalised patient care, has today announced the signing of a five-year SaaS contract with BreastScreen Queensland, after a successful pilot trial with BreastScreen Queensland on the Gold Coast.
BreastScreen Queensland is the third largest public breast screening programme in Australia.
The contract, initially for Volpara’s quality assurance platform, VolparaEnterprise, allows for the expansion of services to include VolparaDensity and VolparaLive. The initial stage will involve the roll-out of VolparaEnterprise to 11 BreastScreen Queensland services operating in Brisbane and elsewhere in the state. The BreastScreen Queensland services comprise 69 gantries and 43 sites that include 10 mobile units, covering 171 radiologists and technologists. The roll-out of VolparaEnterprise to BreastScreen Queensland has already begun, and Volpara expects it to go live in early 2021.
The terms and conditions of the contract with BreastScreen Queensland are confidential.
Volpara Group CEO Dr Highnam said: “Public breast cancer screening programmes around the world do a fantastic job at reducing deaths from breast cancer, and they do so by operating under the strictest quality control, which can make change difficult. “But, we are delighted to now have BreastScreen Queensland signing up to use our software, making it the second major public breast cancer screening programme in Australia signed up to Volpara products. This is news that will resonate around the world, and we are extremely pleased that our software will be helping women in the fight against breast cancer, including women in the lives of many of our long-term investors”.
Authorisation & Additional Information
This announcement was authorised by Dr Ralph Highnam, Group CEO of Volpara Health Technologies Limited.
For further information, please contact:
Ralph Highnam, CEO
Volpara Health Technologies
t: +64 21 149 0541
t: +61 407 933 437
About Volpara Health Technologies Limited (ASX: VHT)
VHT is a health technology software company founded in 2009 on research originally conducted at Oxford University. VHT’s clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice-management software helps with productivity, compliance, reimbursement, and patient tracking.
VHT’s technology and services have been used by customers and/or research projects in 39 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A$132 million, including A$37 million in April/May 2020. VHT is based in Wellington, New Zealand.
or more information, visit www.volparahealth.com